cardiotoxicity

Doxorubicin is a potent chemotherapeutic agent, but its clinical use is limited by dose-dependent cardiotoxicity, which can lead to cardiomyopathy and heart failure. This review discusses the potential of phyto constituent-based nanoformulations as cardioprotective adjuvants against doxorubicin. Encapsulating cardioprotective agents like herbal extracts, antioxidants, and anti-inflammatory co0mpounds encompassing nanoparticles enhances their bioavailability and targeted delivery to cardiomyocytes. Various nanoparticle systems including polymeric (solid lipid), inorganic (mesoporous silica, gold), and nanocomposites have shown promise in mitigating doxorubicin-induced oxidative stress, apoptosis, and cardiac injury in preclinical studies. The therapeutic effects of curcumin, resveratrol, thymoquinone, L-carnitine, and other agents were improved when delivered via nanoparticle. However, optimization of nanoparticle properties, targeted delivery strategies, long-term safety assessments, and clinical translation remain to be addressed. Nonetheless, nanoparticle-mediated delivery of cardioprotective agents holds great potential for reducing doxorubicin-associated cardiotoxicity and improving chemotherapeutic outcomes for cancer patients.